|
|
|||||||||
Clinical Investigations |
1 Medical Research Council Clinical Sciences Centre, Imperial College, London, United Kingdom
2 National Heart and Lung Institute, Imperial College, London, United Kingdom
| ABSTRACT |
|---|
|
|
|---|
Key Words: myocardial blood flow coronary flow reserve ischemic heart disease PET
| INTRODUCTION |
|---|
|
|
|---|
In assessing ischemic heart disease, studies have used several surrogate markers for therapeutic efficacy, including ST segment shift, coronary collateral density, left ventricular function, and semiquantitative assessment of regional MBF. With the advent of more novel therapies, including angiogenic gene therapy, a more physiologically robust endpoint is needed to discriminate between small changes in regional myocardial perfusion (4). Several techniques have been advocated to measure this effect, but all suffer from fundamental limitations. Doppler flow wires only assess epicardial artery flow velocity, coronary angiography cannot visualize vessels <0.5 mm, myocardial contrast echocardiography is operator dependent, and conventional nuclear perfusion scintigraphy is limited by semiquantitative data.
Coronary microcirculatory function can only be tested indirectly by measuring parameters such as MBF and the coronary flow reserve (CFR) (5). PET is the only noninvasive technique that has been validated to provide accurate measurements of absolute regional MBF in humans in vivo (6). CFR, the ratio of hyperemic to baseline MBF, is an integrated parameter of whole coronary circulation. In patients with CAD, CFR provides insight into the functional significance of a coronary stenosis and, in the absence of angiographically detectable CAD, is an index of the integrity of the coronary microcirculation. PET has been widely used to assess CFR in healthy volunteers (7,8) and in patients with CAD (9) and to assess the effect of pharmacologic interventions such as
- (10) and ß-blockade (11) and coronary angioplasty (12).
Vasodilator agents are comparatively short acting and have been shown to have good short-term reproducibility, a property useful in serial consecutive measurements of MBF before and after pharmacologic or therapeutic interventions during the same study session (13). In contrast, the reproducibility of Dob stress has not been extensively studied. In the short-term, this measure is influenced by the comparatively long half-life of the drug as compared with adenosine, but this property will not affect assessment of long-term reproducibility. Little data exist regarding the long-term reproducibility of any pharmacologic stress agents.
Although vasodilators are probably more efficient stressors, the mechanism of Dob hyperemia better mimics physical exercise and arguably provides more relevant insight into the effects of CAD on the coronary circulation. Therefore, we proposed to quantify the long-term reproducibility of resting and Dob-induced hyperemic MBF and CFR measured by PET in patients with stable CAD.
| MATERIALS AND METHODS |
|---|
|
|
|---|
1 mm of horizontal or downsloping ST segment depression. The presence of significant CAD, defined as luminal stenosis of >50% in at least 1 major coronary artery, was confirmed by coronary angiography. Four patients had multivessel disease, but no patient with significant disease in all 3 major vessels was included in this study. Exclusion criteria included a recent history (<3 mo) of myocardial infarction or unstable angina, inability to undergo exercise tolerance testing (ETT), or resting ECG patterns that would interfere with interpretation of ST changes during exercise.
|
Study Design
MBF by PET was measured under resting conditions and during peak Dob stress on 2 occasions: at baseline (time [t] = 0) and at study completion, after 24 wk (t = 24). Angina class (Canadian Cardiovascular Society [CCS]) was scored and ETT was performed following a standard Bruce protocol both at baseline and at study completion. All PET scans were standardized for time of day and fasting state and all antianginal medication was omitted on the day of study.
PET Study Protocol
Scanning (Fig. 1) was performed at the Medical Research Council Clinical Sciences Centre, Hammersmith Hospital, London, with an ECAT 931-08/12 fifteen-slice tomograph (CTI/Siemens) giving a 10.5-cm axial field of view. All emission and transmission data were reconstructed using a Hanning filter with a cutoff frequency of 0.5 unit of the reciprocal of the sampling interval of the projection data, resulting in an axial resolution of 6.6 mm and a transaxial image resolution of 8.5-mm full width at half maximum.
|
PET Data Analysis
PET data analysis was performed by a single operator before disclosure of blinded angiographic findings. The sinograms obtained were corrected for attenuation and reconstructed on a MicroVax II computer (Digital Equipment Corp.) using dedicated array processors and standard reconstruction algorithms. Images were transferred to a SUN SPARC 2 workstation (Sun Microsystems) and analyzed with dedicated software (MATLAB; the MathWorks Inc.). Myocardial images, for the definition of regions of interest (ROIs), were generated directly from the dynamic H215O, as previously reported (14). Briefly, the creation of factor sinograms requires estimates of vascular (right and left heart) and myocardial tissue time-activity curves (14). Factor images describing tissue and blood distributions were generated by iterative reconstruction as previously described (15,16). Factor images were resliced into short-axis images in an orientation perpendicular to the long axis of the left ventricle. Sixteen ROIs, corresponding to the territories of distribution of the 3 major coronary arteries, were drawn within the left ventricular myocardium on 12 consecutive image planes, according to the recommendations of the American Society of Echocardiography (17). The regions were drawn semiautomatically using a center line within the myocardium. The ROIs drawn at baseline and at 24 wk were comparable in size and position. For the present analysis, however, the original 16 left ventricular ROIs were regrouped into 4 larger segments representing septal, anterior, lateral, and inferior walls. A separate set of ROIs was defined for the right ventricular cavity and the left atrium. Myocardial and blood time-activity curves were then generated from the dynamic image and fitted to a single-tissue compartment tracer kinetic model to give values of MBF (mL/min/g) (18). Subsequently, in each patient the myocardial ROI subtended by the most severe coronary stenosis was labeled as Isc, whereas the ROI subtended by an artery with minimal (<50% diameter stenosis) or no disease was labeled as Rem.
Since resting MBF is determined by cardiac work load (19), we corrected resting MBF for the rate·pressure product (RPP), an index of myocardial oxygen consumption: MBF = (MBF/RPP) x 104 (9). CFR was calculated as the ratio of MBF during Dob-induced hyperemia to MBF at rest corrected for RPP. Minimal coronary resistance (arbitrary units) was calculated as the mean pressure divided by MBF (whole left ventricle) during peak Dob infusion.
Statistical Analysis
Comparisons of the hemodynamic, exercise, and PET parameters at t = 0 and t = 24 data were performed by paired Student t tests. A P value < 0.05 was considered statistically significant. The coefficient of variance was calculated as SD/mean. To measure the reproducibility of resting and Dob MBF and CFR, we calculated the repeatability coefficient defined as 1.96 x SD, as proposed by Bland and Altman (20,21) and recommended by the British Standards Institution. Assuming that the data are normally distributed, in 95% of the cases, the difference between the 2 measures will be less than the repeatability coefficient. In addition, the repeatability is given as a percentage of the average value of the 2 measurements, although the results show that the error does not change with the absolute value of the measurement.
| RESULTS |
|---|
|
|
|---|
In our study population, both total treadmill exercise time (425 ± 95 s vs. 499 ± 106 s; P < 0.001) and maximum ST depression during exercise (2.4 ± 1.0 vs. 2.8 ± 1.2 mm; P < 0.02) increased at study completion compared with baseline. These findings probably reflect an effect of training and a greater tolerability of ischemia as described previously (22). To correct for this effect, we calculated the ratio of time achieved to ST depression (s/mm ST depression), which was comparable at baseline and at study completion (206 vs. 211 s/mm; P = not significant [ns])
PET Data
Hemodynamic measurements were similar for rest and Dob stress at baseline and after 24 wk (Table 2). For the values of RPP at rest, we found good repeatability with a coefficient of 2,340that is, 24% of the mean RPP. The absolute repeatability coefficient of RPP during Dob stress was greater at 4,285 mm Hg x beats/min, but this represented a similar proportion (21%) of the mean peak RPP. Dob dose was not different between the 2 studies (30 ± 11 vs. 31 ± 11 µg/kg/min; P = ns).
|
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Reproducibility of MBF at Rest
The long-term reproducibility of MBF under resting conditions was good, with 95% limits of agreement measured within 23% of the mean for global MBF and 27% for regional MBF. Although a significant interindividual heterogeneity of resting MBF has been previously demonstrated (25), a good short-term repeatability in the same healthy individuals has been reported using PET (13). In healthy volunteers, global left ventricular MBF during a single session demonstrated a repeatability coefficient representing 18% of the mean value. However, this was higher for regional MBFthat is, between 22% and 46% of the mean value. Despite the effort made in the present study to standardize some parameters known to affect reproducibilityincluding time of day, smoking, caffeine consumption, and fasting statethe long-term repeatability of resting MBF was inferior to that previously reported in short-term studies. Numerous physiologic variables affect resting MBF, and this difference probably reflects the difficulty to correct for all of these factors if the time interval between the studies is longer.
Previous studies have suggested that repeatability of regional MBF may be more susceptible to variability, specifically due to methodologic reasons, because ROIs with smaller size have poorer counting statistics compared with ROIs with larger size. However, spatial heterogeneity of myocardial perfusion is well accepted (26) and may have influenced our results. Regional variability of perfusion has been observed in the hearts of all species studied thus far (2729) to the extent of 6-fold (30), but the basis for such heterogeneity still lacks a definite explanation. Differences in local metabolic needs, perhaps secondary to differences in regional function, have been suggested (25). Temporal heterogeneities may cause changing variations between regions (31). Spatial heterogeneity in regional MBF has been linked to arteriolar or intratissue oxygen partial pressure over a broad range, from 40 to 200 mm Hg in dogs (32). Furthermore, a linear relationship between coronary flow distribution and tissue norepinephrine content may exist (33). Thus, physiologic heterogeneity may account for the larger variability in segmental MBF and temporal variations may explain, at least in part, the fact that regional MBF measurements are less reproducible than global MBF.
Reproducibility of Hyperemic Blood Flow
The 2 hyperemic measurements of global MBF revealed a repeatability coefficient of 0.58 (28% of the mean value) that indicated worse agreement than that observed for resting MBF. Regional hyperemic MBF for both Isc and Rem territories also demonstrated repeatability coefficients reflecting 27%28% of the mean value. These findings are similar to short-term reproducibility results with adenosine-induced hyperemia. Since MBF during Dob stress is dependent on both RPP and coronary vasodilatation, we estimated the variability of cardiac work and coronary resistance. The latter was considered to reflect indirectly coronary driving pressure during Dob stress. RPP calculated under resting conditions (mean difference, 637) and during Dob hyperemia (mean difference, 691) was comparable (P = ns). Minimal coronary resistance at baseline was similar to that measured at 24 wk (56 ± 15 vs. 54 ± 16 arbitrary units; P = ns). As a result of the reproducibility of MBF measurements, we found similar values for global CFR at baseline and after 24 wk (1.95 ± 0.5 and 1.88 ± 0.45, respectively). However, the repeatability coefficient was 0.64, proportionally representing >33% of the mean. This likely reflects the combination of variability of resting MBF and the hemodynamic response to Dob. Regional CFR measurements also demonstrated higher repeatability coefficients (28%30%) when compared with regional MBF.
Studies of regional blood flow have demonstrated that the distribution of both resting and hyperemic flow is extremely heterogeneous (27), resulting in a wide dispersion of coronary reserve (26). Seemingly, intrinsic properties, such as maximal regional blood flow, vary significantly throughout the heart and over time. Thus, the more modest reproducibility seen with regional CFR may be explained. Repetitive MBF measurements in the same patients have been reported by others, albeit usually to compare estimates of flow using 2 different approaches (34). Previous studies assessing repeatability of regional MBF in healthy volunteers have demonstrated comparatively modest reproducibility (13,24). Explanations include physiologic variability of hyperemic flow and methodologic issues. Our data for regional MBF in ischemic and remote territories in patients with CAD demonstrates much better reproducibility than that seen in control subjects (13,24). Therefore, PET methodologic issues are unlikely to be the main determinant for regional variability. The consistency of regional peak MBF measurements in patients with heart disease suggests that, with peak Dob stress and symptomatic myocardial ischemia, variability in peak MBF is driven by the metabolic demands of myocardium subtended by flow-limiting stenoses. In addition, we found that heterogeneity of peak MBF in remote territories also demonstrated reduced variability compared with previous published regional data in healthy volunteers (13,24). This is in line with previous reports demonstrating alteration of flow reserve in remote territories during severe regional ischemia (35). Values of hyperemic MBF measured in our study are similar to data published in the current literature using Dob stress and PET (36,37). These values are comparable with those attained by bicycle exercise (24) but are significantly lower than the hyperemia achieved with adenosine (13).
How far apart measurements can be made without causing a problem remains a question of judgment for each clinical and individual setting. Nagamachi et al. (38) have reported significant reproducibility of their MBF measurements with PET using 13NH3 and dipyridamole, performed on different days due to the long half-life of the drugs, but they did not provide a repeatability coefficient for their data. Dob has a half-life of
2 min, but its effect on the metabolic demands of myocardial tissue persists well beyond this time, limiting the assessment of reproducibility during a single session. Furthermore, in patients with coronary disease, ischemic insult alters regional myocardial function by a combination of stunning and preconditioning. These physiologic responses to myocardial ischemia remain beyond the pharmacokinetic clearance of Dob and have been shown to persist for a variable length of time (39,40). To obviate these confounding factors we assessed our patients over the long term and chose a time interval that would provide useful information on the variability of resting and Dob-induced MBF for clinical studies assessing the effect of various interventions.
| CONCLUSION |
|---|
|
|
|---|
| FOOTNOTES |
|---|
For correspondence or reprints contact: Paolo G. Camici, MD, Medical Research Council Clinical Sciences Centre, Imperial College of Science Technology and Medicine, Hammersmith Hospital, Du Cane Rd., London W12 0NN, United Kingdom.
E-mail: paolo.camici{at}csc.mrc.ac.uk
| REFERENCES |
|---|
|
|
|---|
Related articles in JNM:
This article has been cited by other articles:
![]() |
P. G. Camici and O. E. Rimoldi The Clinical Value of Myocardial Blood Flow Measurement J. Nucl. Med., July 1, 2009; 50(7): 1076 - 1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. McIntyre, J. O. Burton, N. M. Selby, L. Leccisotti, S. Korsheed, C. S.R. Baker, and P. G. Camici Hemodialysis-Induced Cardiac Dysfunction Is Associated with an Acute Reduction in Global and Segmental Myocardial Blood Flow Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 19 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Kaufmann, O. E. Rimoldi, T. Gnecchi-Ruscone, T. F. Luscher, and P. G. Camici Systemic nitric oxide synthase inhibition improves coronary flow reserve to adenosine in patients with significant stenoses Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2178 - H2182. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T. Siegrist, O. Gaemperli, P. Koepfli, T. Schepis, M. Namdar, I. Valenta, F. Aiello, S. Fleischmann, H. Alkadhi, and P. A. Kaufmann Repeatability of Cold Pressor Test-Induced Flow Increase Assessed with H215O and PET J. Nucl. Med., September 1, 2006; 47(9): 1420 - 1426. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Chareonthaitawee, S. D. Christenson, J. L. Anderson, B. J. Kemp, D. O. Hodge, E. L. Ritman, and R. J. Gibbons Reproducibility of Measurements of Regional Myocardial Blood Flow in a Model of Coronary Artery Disease: Comparison of H215O and 13NH3 PET Techniques J. Nucl. Med., July 1, 2006; 47(7): 1193 - 1201. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Kaufmann, M. Namdar, F. Matthew, M. Roffi, S. V. Aschkenasy, B. van der Loo, G. Sutsch, T. F. Luscher, and R. Jenni Novel Doppler Assessment of Intracoronary Volumetric Flow Reserve: Validation Against PET in Patients With or Without Flow-Dependent Vasodilation J. Nucl. Med., August 1, 2005; 46(8): 1272 - 1277. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |